Format

Send to

Choose Destination
Thorac Cancer. 2016 Mar;7(2):207-14. doi: 10.1111/1759-7714.12315. Epub 2015 Nov 1.

Safety and efficacy of single-agent docetaxel (Taxotere) administered weekly in non-small cell lung carcinoma patients in Korea: An observational study.

Author information

1
Division of Medical Oncology Department of Internal Medicine Yonsei Cancer Center Seoul Korea; Division of Medical Oncology Department of Internal Medicine CHA University Bundang Medical Center Seongnam Korea.
2
Hanyang University College of Medicine Division of Hematology-Oncology Department of Internal Medicine Seoul Korea.
3
Samsung Medical Center Department of Hematology-Oncology Seoul Korea.
4
St. Vincent Hospital Department of Oncology Gyeonggi-do Korea.
5
Seoul National University Bundang Hospital Gyeonggi-do Korea.
6
Daegu Catholic University Hospital Daegu Korea.
7
Kangbuk Samsung Medical Center Seoul Korea.
8
The Catholic University of Korea Seoul St. Mary's Hospital Seoul Korea.
9
Gyeongsang National University Hospital Gyeongsang National University School of Medicine Gyeongnam Korea.
10
NHIC Ilsan Hospital Gyeonggi-do Korea.
11
Korea University Guro Hospital Seoul Korea.
12
Korea Cancer Center Hospital Seoul Korea.
13
Division of Medical Oncology Department of Internal Medicine Yonsei Cancer Center Seoul Korea.

Abstract

BACKGROUND:

To investigate the efficacy, safety, and tolerability of weekly docetaxel treatment in advanced non-small cell lung cancer (NSCLC) patients in Korea.

METHODS:

This prospective observational study included Korean advanced NSCLC patients with Eastern Cooperative Oncology Group performance status <2 who received weekly monotherapy of docetaxel at a dose determined by the physician. Efficacy measurements included tumor response rate, overall survival (OS), progression-free survival, and one-year survival rate. Safety was analyzed through recorded incidences of adverse events (AEs), serious adverse events (SAEs), deaths, and other related safety parameters, along with their toxicity grades.

RESULTS:

Of 274 patients analyzed, one patient achieved a complete response and 42 partial responses; thus, the overall response rate was 15.7%. The OS rate at baseline and at one-year follow-up was 38.3% and 33.8%, respectively. AEs were reported in 229 (83.6%) patients. The most frequently reported hematologic AE of grade ≥3 was a decrease in neutrophils, with 6.6% of the patients developing neutropenia. In non-hematologic AEs of grade ≥3, the most common were infection with unknown absolute neutrophil count and death not associated with Common Terminology Criteria for Adverse Events (CTCAE) (4.7% each). The most common SAE reported was death, not associated with CTCAE (7.3%).

CONCLUSIONS:

In Korean patients, the weekly regimen of docetaxel monotherapy was safe and efficacious against advanced NSCLC.

KEYWORDS:

Carcinoma; docetaxel; non‐small cell lung cancer; safety

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center